320 SOQUEL WAY, SUNNYVALE, CA
Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports Second Quarter 2026 Business Highlights and Financial Results
Letter to Stockholders on 2026 Priorities and Strategic Opportunities
Announces $4.4 Million Financing
FDA Confirms HF II May Support Premarket Approval of Cell Therapy for Ischemic HFrEF
Announces Japan PMDA Record of Advice Supports Regulatory Submission for Approval of Cell Therapy for Ischemic Heart Failure
Q2
Q1
FY 2025
Q3
Amended Quarterly Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload